Literature DB >> 29572347

Bendamustine plus rituximab in chronic lymphocytic leukemia: is there life in the old dog yet?

Clemens-Martin Wendtner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29572347      PMCID： PMC5865432          DOI： 10.3324/haematol.2018.188862

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

2.  Venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Authors:  Kirsten Fischer; Othman Al-Sawaf; Anna-Maria Fink; Mark Dixon; Jasmin Bahlo; Simon Warburton; Thomas J Kipps; Robert Weinkove; Sue Robinson; Till Seiler; Stephen Opat; Carolyn Owen; Javier López; Kathryn Humphrey; Rod Humerickhouse; Eugen Tausch; Lukas Frenzel; Barbara Eichhorst; Clemens-M Wendtner; Stephan Stilgenbauer; Anton W Langerak; Jacque J M van Dongen; Sebastian Böttcher; Matthias Ritgen; Valentin Goede; Mehrdad Mobasher; Michael Hallek
Journal:  Blood       Date:  2017-03-21       Impact factor: 22.113

3.  Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.

Authors:  Qiushi Chen; Nitin Jain; Turgay Ayer; William G Wierda; Christopher R Flowers; Susan M O'Brien; Michael J Keating; Hagop M Kantarjian; Jagpreet Chhatwal
Journal:  J Clin Oncol       Date:  2016-11-21       Impact factor: 44.544

4.  Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.

Authors:  Peter Hillmen; Tadeusz Robak; Ann Janssens; K Govind Babu; Janusz Kloczko; Sebastian Grosicki; Michael Doubek; Panagiotis Panagiotidis; Eva Kimby; Anna Schuh; Andrew R Pettitt; Thomas Boyd; Marco Montillo; Ira V Gupta; Oliver Wright; Iestyn Dixon; Jodi L Carey; Chai-Ni Chang; Steen Lisby; Astrid McKeown; Fritz Offner
Journal:  Lancet       Date:  2015-04-14       Impact factor: 79.321

5.  Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Authors:  Kirsten Fischer; Paula Cramer; Raymonde Busch; Sebastian Böttcher; Jasmin Bahlo; Jöerg Schubert; Karl H Pflüger; Silke Schott; Valentin Goede; Susanne Isfort; Julia von Tresckow; Anna-Maria Fink; Andreas Bühler; Dirk Winkler; Karl-Anton Kreuzer; Peter Staib; Matthias Ritgen; Michael Kneba; Hartmut Döhner; Barbara F Eichhorst; Michael Hallek; Stephan Stilgenbauer; Clemens-Martin Wendtner
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

6.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

Review 7.  Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.

Authors:  Bruce D Cheson; Wolfram Brugger; Gandhi Damaj; Martin Dreyling; Brad Kahl; Eva Kimby; Michinori Ogura; Eckhart Weidmann; Clemens-Martin Wendtner; Pier Luigi Zinzani
Journal:  Leuk Lymphoma       Date:  2015-11-23

8.  Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.

Authors:  Anne-Sophie Michallet; Melih Aktan; Wolfgang Hiddemann; Osman Ilhan; Peter Johansson; Kamel Laribi; Balkis Meddeb; Carol Moreno; João Raposo; Anna Schuh; Ali Ünal; Tom Widenius; Alf Bernhardt; Kerstin Kellershohn; Dimitri Messeri; Stuart Osborne; Véronique Leblond
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.